Denali Therapeutics (DNLI)
NASDAQ:DNLI
Want to see DNLI full AI Analyst Report?
Top Page
Denali Therapeutics
(NASDAQ:DNLI)
Select Model
Select Model
Rating:51Neutral
Price Target:
$22.00
▲(6.95% Upside)
Action:ReiteratedDate:04/01/26
The score is held back primarily by weak financial performance (widening losses, cash burn, and recent $0 revenue) and bearish technical signals. These are partly offset by strong, positive corporate catalysts (FDA accelerated approval and $200M non-dilutive funding) and a low-leverage balance sheet.
Positive Factors
Brain‑penetrant TransportVehicle platform
Denali’s TransportVehicle achieved clinical and regulatory validation with AVLAYAH, demonstrating durable capability to deliver therapeutics across the blood‑brain barrier. A proven delivery platform is a persistent competitive advantage for CNS programs, enabling differentiated indications and faster development paths.
Negative Factors
Sustained cash burn and negative free cash flow
Operating cash flow has moved to persistent outflows and free cash flow remains negative, reflecting structural cash consumption to fund R&D and operations. Continued burn heightens dependence on external financing, limits capacity for discretionary investment, and raises the risk of dilution or onerous funding terms over time.
Read all positive and negative factors
Positive Factors
Negative Factors
Brain‑penetrant TransportVehicle platform
Denali’s TransportVehicle achieved clinical and regulatory validation with AVLAYAH, demonstrating durable capability to deliver therapeutics across the blood‑brain barrier. A proven delivery platform is a persistent competitive advantage for CNS programs, enabling differentiated indications and faster development paths.
Read all positive factors
Denali Therapeutics (DNLI) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$2.90B
Dividend YieldN/A
Average Volume (3M)1.77M
Price to Earnings (P/E)―
Beta (1Y)1.88
Revenue GrowthN/A
EPS Growth-15.30%
CountryUS
Employees443
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.97
Shares Outstanding158,656,310
10 Day Avg. Volume1,198,555
30 Day Avg. Volume1,773,718
Financial Highlights & Ratios
PEG Ratio-0.36
Price to Book (P/B)2.86
Price to Sales (P/S)0.00
P/FCF Ratio-6.86
Enterprise Value/Market Cap0.94
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-956.16
Enterprise Value/Ebitda-5.15
Forecast
1Y Price Target
$36.27Price Target Upside76.34% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
EPS Forecast (FY)-2.58
Revenue Forecast (FY)$40.64M
Denali Therapeutics Business Overview & Revenue Model
Company Description
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122...
How the Company Makes Money
Denali primarily generates revenue through collaboration and licensing arrangements rather than product sales (as it is a clinical-stage company). Its revenue model typically includes: (1) upfront payments received when entering strategic collabor...
Denali Therapeutics Financial Statement Overview
Summary
Income Statement
24
Negative
Balance Sheet
66
Positive
Cash Flow
32
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 330.53M | 108.46M | 48.66M |
| Gross Profit | -11.18M | 0.00 | 330.53M | 108.46M | 48.66M |
| EBITDA | -497.63M | -492.89M | -179.97M | -330.36M | -287.16M |
| Net Income | -512.54M | -422.77M | -145.22M | -325.99M | -290.58M |
Balance Sheet | |||||
| Total Assets | 1.14B | 1.37B | 1.15B | 1.46B | 1.40B |
| Cash, Cash Equivalents and Short-Term Investments | 867.88M | 832.33M | 1.03B | 1.34B | 865.41M |
| Total Debt | 42.29M | 48.71M | 52.24M | 60.35M | 64.01M |
| Total Liabilities | 131.09M | 144.50M | 122.96M | 417.81M | 441.87M |
| Stockholders Equity | 1.01B | 1.23B | 1.03B | 1.04B | 962.29M |
Cash Flow | |||||
| Free Cash Flow | -422.10M | -363.61M | -370.93M | -262.55M | -219.89M |
| Operating Cash Flow | -412.60M | -347.69M | -357.99M | -244.72M | -211.39M |
| Investing Cash Flow | 255.28M | -88.76M | 249.31M | -141.39M | -21.63M |
| Financing Cash Flow | 189.22M | 484.30M | 17.82M | 310.67M | 19.35M |
Denali Therapeutics Technical Analysis
Positive
20.57
Price Trends
20.25
Positive
19.38
Positive
17.20
Positive
Market Momentum
0.06
Negative
52.71
Neutral
73.88
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DNLI, the sentiment is Positive. The current price of 20.57 is above the 20-day moving average (MA) of 19.98, above the 50-day MA of 20.25, and above the 200-day MA of 17.20, indicating a bullish trend. The MACD of 0.06 indicates Negative momentum. The RSI at 52.71 is Neutral, neither overbought nor oversold. The STOCH value of 73.88 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DNLI.
Denali Therapeutics Risk Analysis
Denali Therapeutics disclosed 75 risk factors in its most recent earnings report. Denali Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Denali Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
64 Neutral | $6.07B | -29.60 | -203.17% | ― | ― | -34.71% | |
63 Neutral | $2.92B | -228.91 | -10.26% | ― | 91.34% | 88.80% | |
58 Neutral | $3.15B | 2.92 | -7.31% | ― | 120.01% | 78.83% | |
52 Neutral | $2.48B | -26.90 | -11.10% | ― | 3024.43% | 61.00% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $2.90B | -5.65 | -50.13% | ― | ― | -15.30% | |
48 Neutral | $1.67B | -5.02 | -34.11% | ― | 78.34% | -161.91% |
* Healthcare Sector Average
DNLI
Denali Therapeutics
18.30
2.31
14.45%
AGIO
Agios Pharma
28.16
-1.81
-6.04%
CELC
Celcuity
125.65
114.80
1058.06%
IDYA
IDEAYA Biosciences
28.19
7.72
37.71%
ARQT
Arcutis Biotherapeutics
23.35
7.94
51.52%
BEAM
Beam Therapeutics
30.70
10.88
54.89%
Denali Therapeutics Corporate Events
Business Operations and StrategyProduct-Related Announcements
Denali Regains DNL593 Rights After Takeda Collaboration Ends
Neutral
Apr 3, 2026
On April 3, 2026, Denali Therapeutics said Takeda Pharmaceutical will terminate their 2018 collaboration to co-develop and co-commercialize DNL593, an investigational progranulin replacement therapy for GRN-related frontotemporal dementia. The dec...
Business Operations and StrategyPrivate Placements and Financing
Denali Therapeutics Secures $200 Million Royalty Funding
Positive
Mar 31, 2026
Denali Therapeutics Inc. secured $200 million in gross proceeds on March 27, 2026, upon closing a synthetic royalty funding agreement with Royalty Pharma. The transaction closed shortly after the U.S. Food and Drug Administration granted accelerat...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Denali Therapeutics Gains FDA Approval for AVLAYAH Therapy
Positive
Mar 25, 2026
On March 25, 2026, Denali Therapeutics announced that the U.S. Food and Drug Administration granted accelerated approval to AVLAYAH (tividenofusp alfa-eknm), an enzyme replacement therapy for neurologic manifestations of Hunter syndrome in presymp...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.